Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2128482 | 0.81 | KDM6B (0.47) | MAPTALDH1A1F2CTSD | |
| SCHEMBL2352696 | 0.79 | NAAA (0.50) | MAPTALDH1A1F2CTSDACHE | |
| SCHEMBL6017273 | 0.78 | ALDH1A1 (0.77) | MAPTALDH1A1HRH3 | |
| SCHEMBL11470551 | 0.78 | NAAA (0.53) | MAPTALDH1A1ACHE | |
| SCHEMBL11470387 | 0.78 | NAAA (0.53) | MAPTALDH1A1ACHE | |
| SCHEMBL25383583 | 0.78 | NAAA (0.53) | MAPTALDH1A1ACHE | |
| SCHEMBL11470674 | 0.78 | NAAA (0.53) | MAPTALDH1A1ACHE | |
| SCHEMBL863456 | 0.78 | NAAA (0.53) | MAPTALDH1A1ACHE | |
| SCHEMBL11487106 | 0.78 | NAAA (0.53) | MAPTALDH1A1ACHE | |
| SCHEMBL11477556 | 0.78 | NAAA (0.53) | MAPTALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028920-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-02-02 | — | — | US | disclosed |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20070219191-A1 | 3-Pyridinium Methyl Cephem Compound | SHIONOGI & CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070219191-A1 | 3-Pyridinium Methyl Cephem Compound | SHIONOGI & CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028920-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | MAPT 223/4885ALDH1A1 408/4885HRH3 190/4885 |
| US-20070219191-A1 | 3-Pyridinium Methyl Cephem Compound | ABL1, CRKL, MGMT | MAPT 3767/4885ALDH1A1 3311/4885HRH3 34/4885 |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | GRIN2C, GRIN2B, PMP22 | MAPT 223/4885ALDH1A1 408/4885HRH3 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.